Shaun Grady

Shaun Grady is Senior Vice-President Business Development Operations, leading AstraZeneca’s Global transaction execution, due diligence and Alliance and Integration Management function. This includes early and late-stage Clinical programmes as well as on-market licensing and partnering, M&A, and divestments. His career background includes roles at ICI, Zeneca, and AstraZeneca in Corporate, Pharmaceuticals and US Legal departments, HR and Business Development. Shaun has worked on major projects including the AstraZeneca merger, creation of Avecia and Syngenta, acquisition of Cambridge Antibody Technology (CAT), MedImmune and Amylin, and the spin out of Albireo and more recently AstraZeneca’s Antibody Drug Conjugate collaborations with Daichi Sankyo. Shaun is an Honorary Fellow of the Judge Business School, a Fellow Commoner of Lucy Cavendish College, a Board Member at Healx, Prostate Cancer Research and Cambridge Arts Theatre and Chairman of the Board at Cambridge United Football Club.